This study reported that CD56 expression was significantly associated with risk of lack of response to vismodegib in advanced BCC cohort (OR = 5.5; 95% CI: 3.4–29.8; p = 0.0488), and a similar trend was observed for CXCR4 (OR = 3.45; 95% CI: 0.923–12.96; p = 0.066). Here, NCAM1 is linked to skin basal cell carcinoma.